Q5119 Injection ruxience, 10 milligrams
Also known as: Ruxience injection, rituximab-pvvr
Injection of Ruxience, rituximab-pvvr biosimilar per 10 milligrams, a B-cell surface antigen antagonist.
In Plain Language
lymphoma fighting injection; B-cell targeted therapy
Clinical Context
Indicated for lymphomas, chronic lymphocytic leukemia, and various autoimmune disorders.
RVU Information
CPT Q5119 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5119?
CPT Q5119 (Injection ruxience, 10 milligrams) is a Q Codes code. Injection of Ruxience, rituximab-pvvr biosimilar per 10 milligrams, a B-cell surface antigen antagonist.
Is Q5119 covered by insurance?
Q5119 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Indicated for lymphomas, chronic lymphocytic leukemia, and various autoimmune disorders.
When is CPT Q5119 used?
Indicated for lymphomas, chronic lymphocytic leukemia, and various autoimmune disorders.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.